The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025, in Las Vegas, Nevada, was host to the Moderated Poster 13: Prostate Cancer: Staging Session. Dr. Claudia Kesch ...

Michael Hofman’s presentation at PSMA and Beyond 2025 highlighted the evolving role of the PRIMARY score in prostate cancer diagnosis. The PRIMARY study demonstrated that combining PSMA PET with MRI ...

Prostate cancer (PCa) requires improved diagnostic strategies beyond conventional imaging. This review aimed to evaluate the role of prostate-specific membrane antigen positron emission ...

Perspective on Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery ...

Bildnachweis: FCF, VentureCapital Magazin. Nuclear medicine is currently experiencing a dynamic resurgence, fuelled by ...

MELBOURNE, Australia, April 29, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET 1 imaging agent ...

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa ...

This approval provides healthcare providers in the Czech Republic with broader access to PSMA-PET [3] imaging, using a clinically validated gallium-based radiopharmaceutical. Illuccix, after ...

New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent MELBOURNE, Australia, April 29, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX ...

Illuccix’s broad approval is supported by robust clinical data, including the largest Ga-68-based PSMA data set from the VISION trial 6. The approval of Illuccix® in France has the potential to ...